"FDA Requires Pfizer and Moderna to Update COVID-19 Vaccine Warning Labels for Heart Injury Risk in Young Men"

Read "FDA Requires Pfizer and Moderna to Update COVID-19 Vaccine Warning Labels for Heart Injury Risk in Young Men" on RadioNOVO

"FDA Requires Pfizer and Moderna to Update COVID-19 Vaccine Warning Labels for Heart Injury Risk in Young Men"

[!CDATA[The Food and Drug Administration has instructed Pfizer and Moderna to update the warning labels on their COVID-19 vaccines to include information about the risk of heart injury side effects, particularly in young men. The FDA cited a study from last year and new data from the agency to support this decision. The warning labels for both the Comirnaty and Spikevax vaccines will now specify that males aged 16 to 25 have the highest estimated incidence of myocarditis and pericarditis after receiving the mRNA shots. The rate of these side effects was found to be around 38 cases per million doses in this age group. Previously, both vaccines had warnings about the increased risk of heart side effects in young men, with Moderna's vaccine specifying ages 18 to 24 and Pfizer's vaccine specifying ages 12 to 17. The new blanket warning will now apply to males aged 16 to 25 for both vaccines. The Centers for Disease Control and Prevention has described the rates of myocarditis and pericarditis as rare after COVID-19 vaccination, with acute myocarditis tending to resolve quickly after vaccination. The FDA's decision to expand the warnings was based on new data from the agency's safety surveillance system and findings from a study published in October. The FDA's new warning emphasizes that while myocarditis and pericarditis cases are rare, the highest estimated incidence is in males aged 16 to 25. The agency highlighted that most cases of myocarditis associated with the COVID-19 vaccines had a mild clinical course and showed improvement over time in heart MRI findings. However, it is still unknown whether these findings could predict any long-term effects on the heart. Ongoing studies are being conducted to determine if there are any long-term effects on the heart in individuals who have experienced myocarditis after receiving an mRNA COVID-19 vaccine. In response to the FDA's order, Pfizer and Moderna have the opportunity to dispute the demand within 30 days. The FDA's decision to expand the warning labels comes after a hearing organized by the Senate Homeland Security and Governmental Affairs Committee on the handling of adverse events associated with COVID-19 vaccines. The FDA's focus on updating the warning labels is based on the latest data and research findings to ensure that individuals are informed about the potential risks associated with the vaccines.]]